The BioMed X Institute
19.12.2023 10:03:15 CET | ACCESS Newswire | Press release
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan. The project entitled "New Strategies to Engage Neutrophils in Solid Tumors" will be hosted by the BioMed X Institute in Heidelberg, Germany. The goal of this research project is to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.
Developing immunotherapies that target T cells has proved highly effective, and it is still a rapidly evolving research area. However, many patients remain resistant to these therapies, necessitating the development of novel immunological strategies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems to be paradoxical according to the data accumulated thus far. By uncovering novel neutrophil biology, this project aims to leverage their functions to design novel immunotherapies.
The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C03 before February 18, 2024.
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Oncology and immunology, including tumor immunology, are key areas of expertise at BioMed X. We are proud and honored that Ono has chosen our institute to develop new strategies for engaging neutrophils in cancer therapy".
Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono Pharmaceutical: "We are very pleased to form a partnership with BioMed X in our mission dedicated to overcoming cancer. This innovative research collaboration will engage us with highly talented scientists around the world who possess unique ideas for immunotherapy utilizing neutrophils. We believe that the research team established through this collaboration will lead to the discovery of the next generation of immunotherapy with us".
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
About Ono
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/en.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
View the original press release on newswire.com.
SOURCE: BioMed X Institute
To view this piece of content from stats.newswire.com, please give your consent at the top of this page. To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Tenstorrent Unveils TT-QuietBox(TM) 2, the First RISC-V AI Workstation With a Fully Open-Source Stack to Deliver Teraflop-Class Inference11.3.2026 17:00:00 CET | Press release
Liquid-Cooled Desktop System Runs Models up to 120B Parameters Locally With a Fully Open-Source Stack, Starting at $9,999 SANTA CLARA, CA / ACCESS Newswire / March 11, 2026 / Tenstorrent, the AI computing company led by CEO Jim Keller, today announced TT-QuietBox™ 2 (Blackhole™). This whisper-quiet, liquid-cooled AI workstation runs models up to 120 billion parameters directly at your desk, ships with an entirely open-source software stack from compiler to kernel, and starts at $9,999. It marks the industry's first desktop AI workstation built on RISC-V architecture to deliver teraflop-class inference. The Inference Imperative The timing matters. Inference has quietly overtaken training as the dominant AI workload, now accounting for more than 55% of cloud AI infrastructure spending at $37.5 billion - and it is still accelerating. Yet, developers running these workloads face a stark choice: pay per-token cloud fees that compound as usage scales, or buy hardware locked to proprietary st
Clockwork.io Introduces A New Class of Fault Tolerance to End Failure-Driven GPU Waste in AI Training11.3.2026 14:00:00 CET | Press release
New TorchPass solution addresses a multi-million dollar challenge with AI infrastructure; uses Live GPU Migration to keep large-scale AI training running through hardware failures instead of forcing costly restarts PALO ALTO, CA / ACCESS Newswire / March 11, 2026 / Clockwork.io, the leader in Software-Driven AI Fabrics™- a programmable, vendor-neutral software layer that optimizes large-scale GPU clusters for real-time observability, fault tolerance, and deterministic performance-today announced the general availability of TorchPass Workload Fault Tolerance. This new class of software-driven fault-tolerance eliminates one of the most costly failure modes in large-scale AI training: catastrophic job restarts caused by infrastructure faults. Delivered as a core capability of the Clockwork.io FleetIQ™ platform, TorchPass applies the principles of Software-Driven AI Fabrics to distributed training, using Live GPU Migration to allow workloads to continue running through GPU failures, networ
Datavault AI CEO Nathaniel Bradley to Present at Luminary 2026 During Oscars Weekend in Los Angeles11.3.2026 12:00:00 CET | Press release
Datavault AI (Nasdaq:DVLT) Debuts Tokenized Legacy™ Platform and ADIO® Technology at Beverly Center Alongside Scott Page's My Moon Experience, Pink Floyd Live Performance, and Entertainment Industry Luminaries PHILADELPHIA, PA / ACCESS Newswire / March 11, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, today announced that Chief Executive Officer Nathaniel (Nate) Bradley will deliver a featured presentation at Luminary 2026 - Film, AI, Music and Crypto Innovators, a premier conference taking place Saturday, March 14, 2026, at the Beverly Center (8500 Beverly Blvd, Suite 835, Los Angeles, CA 90048) as part of Oscars Weekend 2026. The Luminary 2026 event is produced by Space Blue/MMF (Dallas Santana) and Hollywood Road Show TV (Chantelle Borelli) and forms the centerpiece of a four-day entertainment and technology activation series running March 1
Context Management Powers Production-Ready AI Analytics at Enterprise Scale11.3.2026 09:00:00 CET | Press release
GoodData delivers governed semantics, grounded knowledge, guided behavior, and full observability for reliable AI analytics. SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / March 11, 2026 / GoodData today introduced Context Management, a governed contextual layer designed to enable production-ready enterprise AI analytics and agents. As organizations deploy AI assistants, copilots, and autonomous agents, they encounter a structural gap: AI lacks enforced business context, governance, and observability. AI pilots demonstrate potential, but moving AI into production exposes the deeper challenge of ensuring answers are consistent, safe, and explainable at scale. Without semantics and traceability, answers shift depending on phrasing. Business rules are applied inconsistently. When outputs change, teams can't explain why. For enterprises, this erodes trust and slows adoption. Many AI analytics platforms rely on prompts, inferred metadata, or loosely integrated document search. Context is sug
Telestream Expands Its Cloud Services with the Introduction of UP11.3.2026 08:05:00 CET | Press release
New cloud-native platform extends Telestream Cloud Services to support Global Ingest, automation, review, and real-time monitoring across hybrid and distributed production environments NEVADA CITY, CA / ACCESS Newswire / March 11, 2026 / Telestream, a global leader in media workflow technologies, today announced the expansion of Telestream Cloud Services with the introduction of UP, a new cloud-native solution designed to support Global Ingest, orchestration, review, and real-time monitoring in modern production environments. With UP, Telestream extends its cloud portfolio beyond high-scale cloud processing and hybrid workflow extension, addressing the growing operational demands of distributed, IP-based media production. As media organizations navigate cost pressures, audience fragmentation, and increasingly distributed production models, cloud adoption has accelerated rapidly but unevenly. Some companies are extending trusted workflows into elastic cloud environments. Others are buil
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom